Physician profile
Keith D Beck
NPI 1740280999
$6,185.18
in general payments reported to CMS, 2019-2025
34 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 92% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $738 · 2021: $1,056 · 2022: $655 · 2023: $569 · 2024: $998 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,560.30 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $1,223.76 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $717.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $445.66 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Avanir Pharmaceuticals, INC. | $209.89 | 2019-2022 | |
| Esperion Therapeutics, INC. | $162.94 | 2021-2024 | Nexletol |
| Lilly USA, LLC | $160.94 | 2019-2024 | Jardiance, Emgality, Zepbound |
| Radius Health, INC. | $156.45 | 2019-2020 | |
| Pfizer INC. | $155.56 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $149.18 | 2019-2021 | |
| Glaxosmithkline, LLC. | $140.29 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $134.49 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.97 | 2024-2025 | |
| Genentech USA, INC. | $89.45 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $86.40 | 2022-2024 | |
| Dexcom, INC. | $77.93 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.96 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.28 | 2019-2025 | Xifaxan |
| Insulet Corporation | $40.13 | 2025 | Omnipod |
| Exact Sciences Corporation | $34.76 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $33.65 | 2020-2021 | |
| Abbott Laboratories | $31.53 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $28.31 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.38 | 2019-2021 | |
| Eisai INC. | $25.15 | 2020-2021 | |
| Philips North America LLC | $24.78 | 2024 | (Ck7) Extended Holter |
| Medtronic, INC. | $24.08 | 2025 | Venaseal |
| Tolmar, INC. | $18.82 | 2025 | Jatenzo |
| Supernus Pharmaceuticals, INC. | $15.89 | 2022 | |
| Currax Pharmaceuticals LLC | $15.35 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $14.60 | 2019 | |
| Ibsa Pharma INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.